Search

Search Constraints

You searched for: Author/Creator Symeonidis, Argiris

Search Results

1. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Issue 12 (December 2018)

2. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. (26th July 2015)

3. Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. Issue 8 (2nd August 2021)

4. Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine. Issue 3 (23rd February 2022)

5. Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry. (6th November 2022)

6. Cover Image. Issue 2 (13th April 2021)

7. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Issue 6 (June 2021)

8. Development of a core outcome set for myelodysplastic syndromes – a Delphi study from the EUMDS Registry Group. (14th May 2020)

9. Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Issue 2 (22nd January 2019)

10. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher‐risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. Issue 4 (26th June 2020)